|
|
|
| Effect of Sharkurba Trivalsartan Sodium in the treatment of chronic heart failure |
| LI Wen-bo |
| Department of Cardiology, Fengcheng People′s Hospital, Jiangxi Province, Fengcheng 331100, China |
|
|
|
|
Abstract Objective To investigate the effect of Sharkurba Trivalsartan Sodium in the treatment of chronic heart failure.Methods A total of 180 cases of patients with chronic heart failure who received treatment in our hospital from January 2017 to January 2019 were selected as subjects, they were divided into control group and study group according to the random number table method, with 90 cases in each group.The control group was treated with Valsartan Capsules, and the study group was treated with Shakurba Triv alsartan Sodium.The clinical effect, the changes of plasma N-terminal frontal brain natriuretic peptide (NT-pro BNP) and exercise tolerance levels were compared between the two groups.Results The total effective rate in the study group was higher than that in the control group, the difference was statistically significant (P＜0.05).After treatment, the plasma NT-pro BNP level in the study group was lower than that in the control group, the difference was statistically significant (P＜0.05).After treatment, the plasma NT-pro BNP level of the two groups was lower than that before treatment, the difference was statistically significant (P＜0.05).After treatment, the 6 min walking distance of the study group was longer than that of the control group, and the blood oxygen saturation (SpO2) level was higher than that of the control group, with statistically significant differences (P＜0.05).After treatment, the 6 min walking distance of both groups was longer than that before treatment, and the SpO2 level was higher than that before treatment, with statistically significant differences (P＜0.05).Conclusion The use of Shakurba Travalsartan Sodium in the treatment of chronic heart failure patients not only has a high clinical efficacy,but also can effectively improve the exercise tolerance of patients and reduce the level of plasma NT-pro BNP , which is worthy of widely use in clinical.
|
|
|
|
|
|
| [1] |
谢诚，叶静，缪丽燕.61 例心力衰竭患者血管紧张素受体脑啡肽酶抑制剂沙库巴曲缬沙坦的应用分析[J].中国药房，2019（8）：1124-1127.
|
| [2] |
许蓓，陈强，周洋，等.学龄期原发性癫痫儿童身心健康状况评估[J].中国医药导报，2018，15（9）：81-84.
|
| [3] |
董蕾，田颖，刘肆仁.沙库巴曲缬沙坦钠片对慢性心力衰竭患者的疗效及对神经内分泌激素活性的影响[J].中国医药，2019，14（5）：655-658.
|
| [4] |
张小红，薛竟宜，李俭强.沙库巴曲缬沙坦治疗心力衰竭的临床应用[J].临床心血管病杂志，2018，34（12）：1215-1218.
|
| [5] |
张相杰，黄文平，许有凡.沙库巴曲缬沙坦和盐酸贝那普利片对心力衰竭患者心室重塑、炎症因子的影响[J].实用医学杂志，2019，35（5）：795-799.
|
| [6] |
王毅，杨征.托伐普坦和沙库巴曲缬沙坦钠片对慢性心力衰竭患者心功能及血清钠水平的影响研究[J].陕西医学杂志，2019，48（4）：470-472.
|
| [7] |
靳海斌.慢性心力衰竭的神经调节治疗及沙库巴曲缬沙坦钠应用新进展[J].心血管病学进展，2019，40（2）：283-286.
|
| [8] |
陈军红，李东野，徐通达.三维超声评价沙库巴曲缬沙坦治疗慢性心力衰竭疗效的研究[J].心肺血管病杂志，2019，38（3）：279-283.
|
| [9] |
李江，曹佳宁，任燕龙.沙库巴曲缬沙坦钠片治疗高原地区高血压慢性心力衰竭患者的临床效果[J].中国医药，2019，14（3）：321-324.
|
| [10] |
范照亮，刘双，谢刚.沙库巴曲缬沙坦对充血性心力衰竭患者血管内皮损伤与心室重塑状态的影响研究[J].中国医学创新，2019，16（8）：51-54.
|
| [11] |
陈海龙.卡维地洛联合沙库巴曲缬沙坦治疗慢性心力衰竭的临床观察[J].锦州医科大学学报，2019，40（1）：22-24.
|
| [12] |
江军，杨莹，杨景美.沙库巴曲缬沙坦钠联合芪参益气滴丸治疗慢性心衰的疗效观察[J].微循环学杂志，2019，29（1）：23-27.
|
| [13] |
赵玉清，刘恒，杨亚楠.沙库巴曲缬沙坦联合胺碘酮治疗合并阵发性房颤的老年性心力衰竭的疗效观察[J].河北医药，2019，41（3）：404-406，410.
|
| [14] |
魏子寒，李栋博，元峥.沙库巴曲缬沙坦治疗左心疾病相关性肺动脉高压的临床研究[J].中国临床药理学与治疗学，2019，24（1）：57-62.
|
| [15] |
张玉珠，赵传艳，曹清涛.沙库巴曲缬沙坦钠与贝那普利治疗慢性心衰的疗效观察[J].世界最新医学信息文摘，2019，19（5）：128-129.
|
| [16] |
朱志玲，王阿妮，林玉璧.沙库巴曲缬沙坦和缬沙坦在慢性心力衰竭患者中的应用效果对比[J].慢性病学杂志，2019，20（1）：105-106，109.
|
| [17] |
朱映华.缬沙坦与卡托普利治疗原发性高血压和慢性心力衰竭临床疗效比较的Meta 分析[J].中国医药科学，2018，8（5）：44-46，50.
|
|
|
|
